# Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer

> **NCT03072238** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 1101 (actual)

## Conditions studied

- Metastatic Prostate Cancer

## Interventions

- **DRUG:** Ipatasertib
- **DRUG:** Abiraterone
- **DRUG:** Placebo
- **DRUG:** Prednisone/Prednisolone

## Key facts

- **NCT ID:** NCT03072238
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-30
- **Primary completion:** 2020-03-16
- **Final completion:** 2024-04-24
- **Target enrollment:** 1101 (ACTUAL)
- **Last updated:** 2025-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03072238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03072238, "Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT03072238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*